Menu

Federal Contractor Misconduct Database (FCMD)

The federal government routinely awards contracts to companies with histories of misconduct, including contract fraud and other violations. POGO believes that providing this website will help to improve contracting decisions and increase public knowledge of how the government spends billions of taxpayer dollars each year. Read more…

Relafen Antitrust Litigation

GlaxoSmithKline agreed to pay $175 million to settle an antitrust lawsuit filed in federal court in Massachusetts accusing the company of blocking cheaper generic forms of its arthritis drug Relafen. The lawsuit was filed on behalf of wholesale purchasers who bought Relafen directly from GSK and resold them to health plans, pharmacies and supermarkets. In August 2001, a court ruled that GSK’s patent covering Relafen was both invalid and unenforceable due to the company’s inequitable conduct.

Misconduct Type
Antitrust
Enforcement Agency
Non-Governmental
Contracting Party
None
Court Type
Civil
Disposition
Settlement
Date of Announcement
2/6/2004
Contractors Involved Penalty
Total
GlaxoSmithKline $175,000,000
Further Information Released
GSK Press Release 8/17/2007

Federal Contractor Misconduct Database